Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Issue 6 (9th October 2015)

• Record Type: Journal Article
• Authors: Prünte, Christian; Fajnkuchen, Franck; Mahmood, Sajjad; Ricci, Federico; Hatz, Katja; Studnička, Jan; Bezlyak, Vladimir; Parikh, Soumil; Stubbings, William John; Wenzel, Andreas; Figueira, João
• Is Part Of: British journal of ophthalmology. Volume 100:Issue 6(2016)
• Page Start: 787
• Page End: 795
• Publication Date: 2015-10-09
• Subjects: Vision -- Clinical Trial -- Macula -- Treatment Medical -- Treatment Lasers; Ophthalmology -- Periodicals; 617.7
• DOI: 10.1136/bjophthalmol-2015-307249
• Languages: English
• ISSNs: 0007-1161

Abstract

Abstract : Aims: To demonstrate non-inferiority of ranibizumab treat-and-extend (T&E) with/without laser to ranibizumab pro re nata (PRN) for best-corrected visual acuity (BCVA) in patients with diabetic macular oedema (DMO). Methods: A 24-month single-masked study with patients randomised 1:1:1 to T&E+laser (n=121), T&E (n=128) or PRN (control; n=123). All patients received monthly injections until BCVA stabilisation. The investigator decided on re-treatment in the PRN and treatment-interval adaptations in the T&E groups based on loss of BCVA stability due to DMO activity. Likewise, laser treatment was at investigator's discretion. Collectively, these features reflect a real-life scenario. Endpoints included mean average change in BCVA from baseline to months 1–12 (primary), mean BCVA change from baseline to months 12 and 24, treatment exposure and safety profile. Results: Both T&E regimens were non-inferior to PRN based on mean average BCVA change from baseline to months 1–12 (T&E+laser: +5.9 and T&E: +6.1 vs PRN: +6.2 letters; both p<0.0001). Mean BCVA change at month 24 was similar across groups (+8.3, +6.5 and +8.1 letters, respectively). The mean number of injections was 12.4 and 12.8 in the T&E+laser and T&E groups and 10.7 in the PRN group. The T&E regimens showed 46% reduction in the number of clinic visits. Over 70% of patients maintained their BCVA, with treatment intervals of ≥2 months over 24 months. Safety profile was consistent with that described in the product information. Conclusions: T&E is a feasible treatment option for patients with DMO, with a potential to reduce treatment burden. Slightly more injections were required versus PRN, likely due to the specifics of the T&E regimen applied here. Trial registration number: NCT01171976.